Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Filings indexed 916 across all filing types
Latest filing 2023-08-21 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Outcome of the Extra-Ordinary General Meeting held on 21st August, 2023
Regulatory Filings
2023-08-21 English
Shareholders meeting
Board/Management Information Classification · 100% confidence The document text is very short (1091 characters) and primarily lists appointments of individuals as directors, specifically mentioning the appointment of a Whole-time Director and a Non-executive Independent Director. There is no financial data, no mention of reports, or regulatory filings beyond these appointments. The content clearly relates to changes in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG).
2023-08-21 English
Financial Results for the quarter ended 30th June, 2023
Regulatory Filings
2023-08-11 English
Financial Result Updates
Regulatory Filings
2023-08-11 English
Statement showing the Un-audited Financial Results (Standalone & Consolidated) of the Company for the first quarter and three months ended 301h June, 2023 alongwith Limited Review Report. ....
Regulatory Filings
2023-08-11 English
Notice of Book Closure for the purpose of Extra-Ordinary General Meeting (EOGM)
Regulatory Filings
2023-08-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.